Can We De-escalate Therapy for HER2-Positive Metastatic Breast Cancer?
Laura A HuppertHope S RugoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
A recent phase Ib/II trial evaluated the combination of tucatinib, letrozole, and palbociclib in patients with HR+/HER2+ metastatic breast cancer, demonstrating a manageable safety profile and encouraging efficacy data. An all-oral, chemotherapy-free regimen is an appealing strategy, and could be a possible maintenance or primary therapy option in select patients.
Keyphrases
- metastatic breast cancer
- end stage renal disease
- ejection fraction
- newly diagnosed
- clinical trial
- prognostic factors
- randomized controlled trial
- study protocol
- type diabetes
- stem cells
- radiation therapy
- polycystic ovary syndrome
- big data
- machine learning
- squamous cell carcinoma
- metabolic syndrome
- deep learning
- rectal cancer
- data analysis